We thank our colleagues Lee Hall, Deirdre Joy, Rick Fairhurst, and Michael O’Neil for helping with the workshop and critically reading this report, and extend our sincere gratitude to all meeting attendees for their active participation in the workshop, thorough and insightful discussions, and valuable recommendations, all summarized in this report. The panel members included John Adams, University of South Florida; Sumana Chakravarty, Steve Hoffman, Kim Lee Sim, Sanaria Inc.; Isabelle Coppens, Fidel Zavala, Johns Hopkins University; Hernando Del Portillo, IS Global; Kirsten Hanson, University of Texas, San Antonio; John Harty, University of Iowa; William Heath, University of Melbourne; Volker Heussler, University of Bern; Stefan Kappe, Ashley M. Vaughan, Center of Infectious Diseases Research; Shahid Khan, Leiden University Medical Center; Carole Long, NIAID; Sebastian Lourido, Whitehead Institute; Jacquin Niles, Massachusetts Institute of Technology; Miguel Prudencio, Instituto de Medicina Molecular; Robert Sauerwein, Radboud University Medical Center; Boris Striepen, University of Pennsylvania; Norman Waters, Walter Reed Army Institute of Research; and Elizabeth Winzeler, University of California at San Diego. We also acknowledge Ashley M. Vaughan and Jacquin Niles for providing detailed meeting notes after the workshop.
World Health Organization, 2017. WHO Global Vaccine Action Plan (GVAP). Available at: www.who.int/entity/immunization/global_vaccine_action_plan/web_gvap_secretariat_report_2017.pdf. Accessed July 30, 2018.
World Health Organization, 2013. WHO Malaria Vaccine Technology Roadmap. Available at: http://www.who.int/immunization/topics/malaria/vaccine_roadmap/en/. Accessed July 30, 2018.
RTS,S Clinical Trials Partnership, 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386: 31–45.
Mendes AM, Scholzen A, Mueller AK, Khan SM, Sauerwain RW, Prudencio M, 2017. Whole organism pre-erythrocytic vaccines. Rodrgue A, Mota MM, eds. Malaria: Immune Response to Infection and Vaccination. Cham, Switzerland: Spinger International Publishing, 121–122.
Seder RA et al. VRC 312 Study Team, 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 1359–1365.
Ishizuka AS et al. 2016. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22: 614–623. Erratum in: Nat Med 22: 692.
Lyke KE et al. 2017. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA 114: 2711–2716.
Sissoko MS et al. 2017. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 17: 498–509.
Polhemus ME et al. 2009. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One 4: e6465.
Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT, 2011. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9: 451–462.
Spring M et al. 2013. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31: 4975–4983.
Mikolajczak SA et al. 2014. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther 22: 1707–1715.
Fernandez-Ruiz D et al. 2016. Liver-resident memory CD8+ T cells form a front-line defense against malaria liver-stage infection. Immunity 45: 889–902.
Roth A et al. 2018. A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. Nat Commun 9: 1837.